Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Depreciation & Amortization (CF) (2020 - 2025)

Foghorn Therapeutics has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $832000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $832000.0 for Q4 2025, up 9.33% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (up 10.85% YoY), and the annual figure for FY2025 was $3.3 million, up 6.79%.
  • Depreciation & Amortization (CF) for Q4 2025 was $832000.0 at Foghorn Therapeutics, down from $900000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for FHTX hit a ceiling of $900000.0 in Q3 2022 and a floor of $700000.0 in Q3 2024.
  • Median Depreciation & Amortization (CF) over the past 5 years was $805500.0 (2021), compared with a mean of $822950.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 300.0% in 2021 and later dropped 22.22% in 2024.
  • Foghorn Therapeutics' Depreciation & Amortization (CF) stood at $783000.0 in 2021, then increased by 5.62% to $827000.0 in 2022, then grew by 2.9% to $851000.0 in 2023, then decreased by 10.58% to $761000.0 in 2024, then grew by 9.33% to $832000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $832000.0 (Q4 2025), $900000.0 (Q3 2025), and $900000.0 (Q2 2025) per Business Quant data.